Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
前收盤價
US$319.4
+US$1.88 · +0.59%
盤中時間採用ET。市場資料可能有所延遲。
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
日內區間
目前US$319.4
52週區間
目前US$319.4
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 14.04億 USD | 11.95億 USD | 10.59億 USD | 8.47億 USD | 7.48億 USD |
| 銷貨成本 | 4.61億 USD | 4.4億 USD | 3.76億 USD | 3.12億 USD | 2.72億 USD |
| 毛利 | 9.42億 USD | 7.55億 USD | 6.83億 USD | 5.35億 USD | 4.75億 USD |
| 研究與開發 | 8976.6萬 USD | 9478.3萬 USD | 8442.3萬 USD | 7940.7萬 USD | 1.05億 USD |
| 銷售、一般及管理費用 | 6.63億 USD | 5.74億 USD | 5.06億 USD | 4.5億 USD | 3.78億 USD |
| 營業費用 | 7.53億 USD | 6.69億 USD | 6.09億 USD | 5.29億 USD | 4.83億 USD |
| 利息收入 | 1629.4萬 USD | 1369萬 USD | 682.5萬 USD | 188.6萬 USD | 287.1萬 USD |
| 利息支出 | 131.1萬 USD | 141.8萬 USD | 173.9萬 USD | 174.9萬 USD | 193.3萬 USD |
| 折舊和攤銷 | 1747.1萬 USD | 2370.2萬 USD | 2725.7萬 USD | 2432.1萬 USD | 1640.8萬 USD |
| 營業利益 | 1.89億 USD | 8622.4萬 USD | 7355.1萬 USD | 608.2萬 USD | −750.1萬 USD |
| 淨利 | 1.78億 USD | 1401.2萬 USD | 9095.4萬 USD | −200.2萬 USD | 528.4萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$320
上漲空間 0.19%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2014年11月16日 | 1:10 | — | — |
已生效 2014年11月16日
1:10
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3.83億0.02%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB2.78億0.15%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK1.59億0.35%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF1.48億0.15%954億 USD0.05%US$235+0.80%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY9377萬0.36%258.17億 USD0.23%US$669.87+0.54%
iShares Russell Mid-Cap Growth ETFIWP6804.45萬0.34%200.95億 USD0.23%US$143.1+1.56%
State Street SPDR Portfolio S&P 400 Mid Cap ETFSPMD6691.46萬0.37%182.7億 USD0.03%US$64.33+0.56%
iShares U.S. Medical Devices ETFIHI6183.92萬1.75%35.74億 USD0.37%US$51.74+1.25%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
State Street SPDR S&P MIDCAP 400 ETF TrustMDY
iShares Russell Mid-Cap Growth ETFIWP
State Street SPDR Portfolio S&P 400 Mid Cap ETFSPMD
iShares U.S. Medical Devices ETFIHIAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。